WIPO logo
Mobile | Deutsch | Español | Français | 日本語 | 한국어 | Português | Русский | 中文 | العربية |
PATENTSCOPE

Search International and National Patent Collections
World Intellectual Property Organization
Search
 
Browse
 
Translate
 
Options
 
News
 
Login
 
Help
 
Machine translation
1. (WO2018006801) ORPHAN NUCLEAR RECEPTOR NUR77 LIGAND AND APPLICATION THEREOF 
Latest bibliographic data on file with the International Bureau    Submit observation

Pub. No.:    WO/2018/006801    International Application No.:    PCT/CN2017/091716
Publication Date: 11.01.2018 International Filing Date: 04.07.2017
IPC:
C07J 63/00 (2006.01), A61K 31/56 (2006.01), A61K 31/015 (2006.01), A61P 3/04 (2006.01)
Applicants: XIAMEN UNIVERSITY [CN/CN]; No.422 Si Ming Nan Road, Siming District Xiamen, Fujian 361005 (CN)
Inventors: ZHANG, Xiaokun; (CN).
LIN, Xiangzhi; (CN).
SU, Ying; (CN).
ZENG, Zhiping; (CN).
HU, Mengjie; (CN).
LUO, Qiang; (CN).
ZHU, Yi; (CN).
GULIMIRAN, Alitongbieke; (CN)
Agent: CCPIT PATENT AND TRADEMARK LAW OFFICE; 8th Floor, Vantone New World Plaza 2 Fuchengmenwai Street, Xicheng District Beijing 100037 (CN)
Priority Data:
201610520308.8 04.07.2016 CN
Title (EN) ORPHAN NUCLEAR RECEPTOR NUR77 LIGAND AND APPLICATION THEREOF 
(FR) LIGAND DU RÉCEPTEUR NUCLÉAIRE ORPHELIN NUR77 ET SON APPLICATION 
(ZH) 孤儿核受体Nur77的配体及其用途 
Abstract: front page image
(EN)The present application relates to an orphan nuclear receptor Nur77 ligand and an application thereof. The application specifically relates to a compound represented by formula I and application of the compound as the orphan nuclear receptor Nur77 ligand. The application further relates to an application of the compound represented by formula I for preventing or treating a disease related to the orphan nuclear receptor Nur77.
(FR)La présente invention concerne un ligand du récepteur nucléaire orphelin Nur77 et une application de celui-ci. L'invention concerne spécifiquement un composé représenté par la formule I et l'application du composé en tant que ligand du récepteur nucléaire orphelin Nur77. L'invention concerne en outre une application du composé représenté par la formule I pour prévenir ou traiter une maladie liée au récepteur nucléaire orphelin Nur77.
(ZH)本申请涉及孤儿核受体Nur77的配体及其用途。特别地,本申请涉及如式I所示的化合物用作孤儿核受体Nur77的配体的用途。此外,本申请还涉及如式I所示的化合物用于预防或治疗与孤儿核受体Nur77相关的疾病的用途,
Designated States: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.
African Regional Intellectual Property Organization (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Organization (AM, AZ, BY, KG, KZ, RU, TJ, TM)
European Patent Office (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).
Publication Language: Chinese (ZH)
Filing Language: Chinese (ZH)